#AANAM – Tasigna Shows Sustained Safety in Phase 2 Trial, Larger Study Favored

#AANAM – Tasigna Shows Sustained Safety in Phase 2 Trial, Larger Study Favored

292247

#AANAM – Tasigna Shows Sustained Safety in Phase 2 Trial, Larger Study Favored

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Tasigna (nilotinib), an approved leukemia medication, was seen to be safe and tolerable at high and low dose in people with Parkinson’s disease enrolled for more than two years in a Phase 2 trial, with no apparent treatment-related adverse side effects. Greater benefits were also seen in disease symptoms…

You must be logged in to read/download the full post.